Optimal target blood pressure for major adverse cardiovascular and cerebrovascular events in hypertensive patients

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Seon-Mi Kim ◽  
Do-Hyang Kim ◽  
Dong-Ryeol Ryu ◽  
Soojin Lee ◽  
Yaerim Kim ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Target Blood Pressure ◽  
Hypertensive Patients ◽  
Cerebrovascular Events ◽  
Optimal Target

Therapieziele bei der Hypertoniebehandlung

2017 ◽  
Vol 142 (19) ◽  
pp. 1420-1429 ◽  
Author(s):  
Rainer Düsing
Keyword(s):  
Blood Pressure ◽  
Cardiovascular Risk ◽  
Systolic Blood Pressure ◽  
Measurement Procedure ◽  
Treatment Goals ◽  
High Cardiovascular Risk ◽  
Hypertensive Patients ◽  
Optimal Target ◽  
Elderly Hypertensive ◽  
Intervention Trials

AbstractThe optimal target blood pressure (BP) in the treatment of hypertensive patients remains controversial. Recently, the systolic blood pressure trial (SPRINT) has proposed that a target systolic blood pressure of < 120 mmHg provides prognostic benefit in elderly hypertensive patients at high cardiovascular risk. The results of SPRINT contrast with several other intervention trials which have investigated the effect of intense BP lowering (Secondary Prevention of Small Subcortical Strokes [SPS3], Action to Control Cardiovascular Risk in Diabetes [ACCORD], Heart Outcomes Prevention Evaluation [HOPE]-3). The differences in outcomes in SPRINT vs. other intervention trials are, to a large extend, due to an "unobserved" BP measurement procedure utilized in the SPRINT trial. Thus, a BP goal of < 120 mmHg, at least by conventional BP measurement, remains unproven. Independent of SPRINT the controversial evidence with respect to BP targets calls for further studies and, possibly, for more individualized treatment goals.

Determining the optimal target blood pressure after thrombectomy

Neurology ◽  
2017 ◽  
Vol 89 (6) ◽  
pp. 528-529 ◽  
Author(s):  
Katja E. Wartenberg ◽  
Stephan A. Mayer
Keyword(s):  
Blood Pressure ◽  
Target Blood Pressure ◽  
Optimal Target

[PP.24.19] THE IMPACT OF TARGET BLOOD PRESSURE LEVELS ON THE DIASTOLIC FUNCTION OF THE LEFT VENTRICLE IN HYPERTENSIVE PATIENTS

2017 ◽  
Vol 35 ◽  
pp. e292-e293
Author(s):  
D. Mytas ◽  
S. Patsianis ◽  
D. Aravantinos ◽  
V. Kakiouzi ◽  
A. Seretis ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Left Ventricle ◽  
Diastolic Function ◽  
Target Blood Pressure ◽  
Hypertensive Patients ◽  
The Impact

Target blood pressure in elderly hypertensive patients and in patients with diabetes mellitus

2014 ◽  
Vol 32 (8) ◽  
pp. 1551-1552 ◽  
Author(s):  
Giuseppe Mancia ◽  
Robert Fagard ◽  
Krzysztof Narkiewicz ◽  
Josep Redon ◽  
Alberto Zanchetti
Keyword(s):  
Diabetes Mellitus ◽  
Blood Pressure ◽  
Target Blood Pressure ◽  
Hypertensive Patients ◽  
Patients With Diabetes ◽  
Elderly Hypertensive ◽  
Elderly Hypertensive Patients

scholarly journals Optimal target blood pressure in critically ill adult patients with vasodilatory shock: a protocol for a systematic review and meta-analysis

BMJ Open ◽  
2021 ◽  
Vol 11 (3) ◽  
pp. e048512
Author(s):  
Satoshi Fukui ◽  
Koki Higashio ◽  
Shuhei Murao ◽  
Akira Endo ◽  
Takasu Akira ◽  
...  
Keyword(s):  
Systematic Review ◽  
Blood Pressure ◽  
Critically Ill ◽  
Meta Analysis ◽  
Target Blood Pressure ◽  
Adult Patients ◽  
Controlled Trials ◽  
Cochrane Central Register ◽  
Vasodilatory Shock ◽  
Optimal Target

IntroductionThe optimal target of mean arterial pressure (MAP) for better outcomes in patients with vasodilatory shock remains a matter of debate. Although catecholamines are generally used to maintain target blood pressure in hypotensive patients with vasodilatory shock, the adverse effects of catecholamines must also be considered. We will perform a systematic review and meta-analysis of randomised controlled trials (RCTs) to assess the certainty of evidence determining the optimal target of MAP control for patients with vasodilatory shock in critically ill settings.Methods and analysisThis study protocol was registered in the University Hospital Medical Information Network Clinical Trials Registry. We will include only RCTs that evaluated the two different comparators for target MAP to be maintained for clinical outcomes of all-cause mortality: organ dysfunction and adverse events in critically ill adult patients with vasodilatory shock. We will search the electronic bibliographic databases of MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials in November 2020. Two reviewers will independently screen titles and abstracts, perform full article reviews and extract study data. We will report study characteristics and assess methodological quality using the Cochrane Risk-of-Bias 2 tool. If pooling is appropriate, we will calculate relative risks with 95% CIs for all outcome measures. Clinical and methodological subgroup and sensitivity analyses will be performed to explore heterogeneity. Overall certainty of evidence will be evaluated using the Grading of Recommendations Assessment, Development and Evaluation approach.Ethics and disseminationThis study will not involve primary data collection, and formal ethics approval will therefore not be required. We aim to publish this systematic review in a peer-reviewed journal.Trial registration numberUMIN000042624.

Sign in / Sign up

Export Citation Format

Share Document